{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:15:29Z","timestamp":1788912929623,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,30]]},"DOI":"10.7759\/cureus.10145","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T05:56:31Z","timestamp":1598853391000},"source":"Crossref","is-referenced-by-count":6,"title":["Statins and Abnormal Liver Function Tests: Is There a Correlation?"],"prefix":"10.7759","author":[{"given":"Jibran","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ali Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Minhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Khatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawaja M","family":"Aarij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dr. Muhammad","family":"Shehzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq M","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00441.2016","article-title":"Rationale for the use of statins in liver disease","volume":"312","author":"Schierwagen R","year":"2017","unstructured":"Schierwagen R, Uschner FE, Magdaleno F, Klein S, Trebicka J. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol. 2017, 312:407-412. 10.1152\/ajpgi.00441.2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.2174\/157488609789006949","article-title":"Adverse effects of statins - mechanisms and consequences","volume":"4","author":"Be\u0142towski J","year":"2009","unstructured":"Be\u0142towski J, W\u00f3jcicka G, Jamroz-Wi\u015bniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf. 2009, 4:209-228.","journal-title":"Curr Drug Saf"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori CR","year":"2014","unstructured":"Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014, 88:3-11. 10.1016\/j.phrs.2014.03.002","journal-title":"Pharmacol Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.11.020","article-title":"Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany","volume":"268","author":"M\u00e4rz W","year":"2018","unstructured":"M\u00e4rz W, Dippel FW, Theobald K, Gorcyca K, Iorga SR, Ansell D. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis. 2018, 268:99-107. 10.1016\/j.atherosclerosis.2017.11.020","journal-title":"Atherosclerosis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61730-X","article-title":"Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials","volume":"385","author":"Mega JL","year":"2015","unstructured":"Mega JL, Stitziel NO, Smith JG, et al.. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015, 385:2264-2271. 10.1016\/S0140-6736(14)61730-X","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000100908","article-title":"Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program","volume":"107","author":"Shepherd J","year":"2007","unstructured":"Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology. 2007, 107:433-443. 10.1159\/000100908","journal-title":"Cardiology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2015.10.005","article-title":"Biochemistry of statins","volume":"73","author":"Egom EE","year":"2016","unstructured":"Egom EE, Hafeez H. Biochemistry of statins. Adv Clin Chem. 2016, 73:127-168. 10.1016\/bs.acc.2015.10.005","journal-title":"Adv Clin Chem"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson PD","year":"2016","unstructured":"Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016, 67:2395-2410. 10.1016\/j.jacc.2016.02.071","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.2174\/1381612820666141013134447","article-title":"Adverse effects of statins - myths and reality","volume":"21","author":"\u0160imi\u0107 I","year":"2015","unstructured":"\u0160imi\u0107 I, Reiner \u017d. Adverse effects of statins - myths and reality. Curr Pharm Des. 2015, 21:1220-1226.","journal-title":"Curr Pharm Des"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu C","year":"2001","unstructured":"Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001, 5:378-387. 10.1111\/j.1582-4934.2001.tb00172.x","journal-title":"J Cell Mol Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey D","year":"2016","unstructured":"Katarey D, Verma S. Drug-induced liver injury. Clin Med. 2016, 16:104-109. 10.7861\/clinmedicine.16-6-s104","journal-title":"Clin Med"},{"key":"ref12","article-title":"Statins and elevated liver tests: what's the fuss?","volume":"57","author":"Onusko E","year":"2008","unstructured":"Onusko E. Statins and elevated liver tests: what's the fuss?. J Fam Pract. 2008, 57:449-452.","journal-title":"J Fam Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo PY","year":"2017","unstructured":"Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017, 112:18-35. 10.1038\/ajg.2016.517","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0b013e328347036f","article-title":"Liver function tests and statins","volume":"26","author":"Zamor PJ","year":"2011","unstructured":"Zamor PJ, Russo MW. Liver function tests and statins. Curr Opin Cardiol. 2011, 26:338-341. 10.1097\/HCO.0b013e328347036f","journal-title":"Curr Opin Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis","volume":"376","author":"Athyros VG","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD, et al.. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010, 376:1916-1922. 10.1016\/S0140-6736(10)61272-X","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.219","article-title":"Pharmacotherapy: statins are safe in NAFLD","volume":"8","author":"Mearns BM","year":"2011","unstructured":"Mearns BM. Pharmacotherapy: statins are safe in NAFLD. Nat Rev Cardiol. 2011, 8:65. 10.1038\/nrcardio.2010.219","journal-title":"Nat Rev Cardiol"},{"key":"ref17","article-title":"Statins for patients with nonalcoholic fatty liver?","volume":"60","author":"Egan M","year":"2011","unstructured":"Egan M, Prasad S. Statins for patients with nonalcoholic fatty liver?. J Fam Pract. 2011, 60:536-538.","journal-title":"J Fam Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp17X689365","article-title":"Reducing liver function tests for statin monitoring: an observational comparison of two clinical commissioning groups","volume":"67","author":"Homer K","year":"2017","unstructured":"Homer K, Robson J, Solaiman S, et al.. Reducing liver function tests for statin monitoring: an observational comparison of two clinical commissioning groups. Br J Gen Pract. 2017, 67:194-200. 10.3399\/bjgp17X689365","journal-title":"Br J Gen Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20X101066","article-title":"The rise of the statins and the burdening inefficiencies in liver monitoring","volume":"20","author":"Al-Gailani H","year":"2020","unstructured":"Al-Gailani H, Chadha P. The rise of the statins and the burdening inefficiencies in liver monitoring. BJGP Open. 2020, 20:101066. 10.3399\/bjgpopen20X101066","journal-title":"BJGP Open"},{"key":"ref20","article-title":"Chronic liver disease related mortality pattern in Northern Pakistan","volume":"13","author":"Khokhar N","year":"2003","unstructured":"Khokhar N, Niazi SA. Chronic liver disease related mortality pattern in Northern Pakistan. J Coll Physicians Surg Pak. 2003, 13:495-549.","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.06.004","article-title":"Rosuvastatin 5 and 10 mg\/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies","volume":"28","author":"Glueck CJ","year":"2006","unstructured":"Glueck CJ, Aregawi D, Agloria M, et al.. Rosuvastatin 5 and 10 mg\/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther. 2006, 28:933-942. 10.1016\/j.clinthera.2006.06.004","journal-title":"Clin Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730020-00005","article-title":"Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients","volume":"30","author":"Kasliwal R","year":"2007","unstructured":"Kasliwal R, Wilton LV, Cornelius V, Aurich-Barrera B, Shakir SAW. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients. Drug Saf. 2007, 30:157-170. 10.2165\/00002018-200730020-00005","journal-title":"Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/39714-statins-and-abnormal-liver-function-tests-is-there-a-correlation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:21:40Z","timestamp":1707506500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/39714-statins-and-abnormal-liver-function-tests-is-there-a-correlation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,30]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.10145","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,30]]}}}